NADOLOL- nadolol tablet Amneal Pharmaceuticals NY LLC


Nadolol Tablets, USP

(20 mg, 40 mg, and 80 mg)

Rx Only

DESCRIPTION

Nadolol tablets, USP are a synthetic nonselective beta-adrenergic receptor blocking agent designated chemically as 1-(*tert*-butylamino)-3-[(5, 6, 7, 8-tetrahydro-*cis*-6, 7-dihydroxy-1-naphthyl) oxy]-2-propanol. Structural formula:



C₁₇H₂₇NO₄

MW 309.40

Nadolol, USP is a white crystalline powder. It is freely soluble in ethanol, soluble in hydrochloric acid, slightly soluble in water and in chloroform, and very slightly soluble in sodium hydroxide.

Nadolol tablets, USP are available for oral administration as 20 mg, 40 mg, and 80 mg tablets. Inactive ingredients: microcrystalline cellulose, maize starch, magnesium stearate and povidone.

CLINICAL PHARMACOLOGY

Nadolol is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia.

Nadolol specifically competes with beta-adrenergic receptor agonists for available beta

receptor sites; it inhibits both the beta₁ receptors located chiefly in cardiac muscle and the beta₂ receptors located chiefly in the bronchial and vascular musculature, inhibiting the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation proportionately. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane- stabilizing action. Animal and human studies show that nadolol slows the sinus rate and depresses AV conduction. In dogs, only minimal amounts of nadolol were detected in the brain relative to amounts in blood and other organs and tissues. Nadolol has low lipophilicity as determined by octanol/water partition coefficient, a characteristic of certain beta-blocking agents that has been correlated with the limited extent to which these agents cross the blood-brain barrier, their low concentration in the brain, and low incidence of CNS-related side effects.

In controlled clinical studies, nadolol at doses of 40 to 320 mg/day has been shown to decrease both standing and supine blood pressure, the effect persisting for approximately 24 hours after dosing.

The mechanism of the antihypertensive effects of beta-adrenergic receptor blocking agents has not been established; however, factors that may be involved include (1) competitive antagonism of catecholamines at peripheral (non-CNS) adrenergic neuron sites (especially cardiac) leading to decreased cardiac output, (2) a central effect leading to reduced tonic-sympathetic nerve outflow to the periphery, and (3) suppression of renin secretion by blockade of the beta-adrenergic receptors responsible for renin release from the kidneys.

While cardiac output and arterial pressure are reduced by nadolol therapy, renal hemodynamics are stable, with preservation of renal blood flow and glomerular filtration rate.

By blocking catecholamine-induced increases in heart rate, velocity and extent of myocardial contraction, and blood pressure, nadolol generally reduces the oxygen requirements of the heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, nadolol can increase oxygen requirements by increasing left ventricular fiber length and end diastolic pressure, particularly in patients with heart failure.

Although beta-adrenergic receptor blockade is useful in treatment of angina and hypertension, there are also situations in which sympathetic stimulation is vital. For example, in patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. Beta-adrenergic blockade may worsen AV block by preventing the necessary facilitating effects of sympathetic activity on conduction. Beta₂-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to bronchospasm and may also interfere with exogenous bronchodilators in such patients.

Absorption of nadolol after oral dosing is variable, averaging about 30 percent. Peak serum concentrations of nadolol usually occur in three to four hours after oral administration and the presence of food in the gastrointestinal tract does not affect the rate or extent of nadolol absorption. Approximately 30 percent of the nadolol present in serum is reversibly bound to plasma protein.

Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the

liver and is excreted unchanged, principally by the kidneys.

The half-life of therapeutic doses of nadolol is about 20 to 24 hours, permitting oncedaily dosage. Because nadolol is excreted predominantly in the urine, its half-life increases in renal failure (see **PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**). Steady-state serum concentrations of nadolol are attained in six to nine days with oncedaily dosage in persons with normal renal function. Because of variable absorption and different individual responsiveness, the proper dosage must be determined by titration.

Exacerbation of angina and, in some cases, myocardial infarction and ventricular dysrhythmias have been reported after abrupt discontinuation of therapy with betaadrenergic blocking agents in patients with coronary artery disease. Abrupt withdrawal of these agents in patients without coronary artery disease has resulted in transient symptoms, including tremulousness, sweating, palpitation, headache, and malaise. Several mechanisms have been proposed to explain these phenomena, among them increased sensitivity to catecholamines because of increased numbers of beta receptors.

INDICATIONS AND USAGE

Angina Pectoris

Nadolol tablets are indicated for the long-term management of patients with angina pectoris.

Hypertension

Nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol tablets.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk

reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Nadolol tablets may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

CONTRAINDICATIONS

Nadolol tablets are contraindicated in bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure (see **WARNINGS**).

WARNINGS

Cardiac Failure

Sympathetic stimulation may be a vital component supporting circulatory function in patients with congestive heart failure, and its inhibition by beta-blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.

IN PATIENTS WITHOUT A HISTORY OF HEART FAILURE, continued use of beta-blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, the patient should be digitalized and/or treated with diuretics, and the response observed closely, or nadolol should be discontinued (gradually, if possible).

Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal-

Hypersensitivity to catecholamines has been observed in patients withdrawn from betablocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after *abrupt* discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.

Nonallergic Bronchospasm (e.g., chronic bronchitis, emphysema)

PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD IN GENERAL NOT RECEIVE BETA-BLOCKERS. Nadolol should be administered with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta₂ receptors.

Major Surgery

Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

Diabetes and Hypoglycemia

Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs.

Thyrotoxicosis

Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm.

PRECAUTIONS

Impaired Renal Function

Nadolol should be used with caution in patients with impaired renal function (see **DOSAGE AND ADMINISTRATION**).

Information for Patients

Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of nadolol therapy without the physician's advice. Although cardiac failure rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure. The patient should also be advised of a proper course in the event of an inadvertently missed dose.

Drug Interactions

When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents:

Anesthetics, general—exaggeration of the hypotension induced by general anesthetics (see **WARNINGS, Major Surgery**).

Antidiabetic drugs (oral agents and insulin)—hypoglycemia or hyperglycemia; adjust dosage of antidiabetic drug accordingly (see **WARNINGS, Diabetes and**

Hypoglycemia).

Catecholamine-depleting drugs (e.g., reserpine)—additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension).

Digitalis glycosides—Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Response to Treatment for Anaphylactic Reaction—While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In chronic oral toxicology studies (one to two years) in mice, rats, and dogs, nadolol did not produce any significant toxic effects. In two-year oral carcinogenic studies in rats and mice, nadolol did not produce any neoplastic, preneoplastic, or non-neoplastic pathologic lesions. In fertility and general reproductive performance studies in rats, nadolol caused no adverse effects.

Pregnancy

Category C

In animal reproduction studies with nadolol, evidence of embryo- and fetotoxicity was found in rabbits, but not in rats or hamsters, at doses 5 to 10 times greater (on a mg/kg basis) than the maximum indicated human dose. No teratogenic potential was observed in any of these species. There are no adequate and well-controlled studies in pregnant women. Nadolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates whose mothers are receiving nadolol at parturition have exhibited bradycardia, hypoglycemia, and associated symptoms.

Nursing Mothers

Nadolol is excreted in human milk. Because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or to discontinue therapy taking into account the importance of nadolol to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

Most adverse effects have been mild and transient and have rarely required withdrawal of therapy.

Cardiovascular

Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and

heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also **CONTRAINDICATIONS**, **WARNINGS**, and **PRECAUTIONS**).

Central Nervous System

Dizziness or fatigue has been reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior have each been reported in approximately 6 of 1,000 patients.

Respiratory

Bronchospasm has been reported in approximately 1 of 1,000 patients (see **CONTRAINDICATIONS** and **WARNINGS**).

Gastrointestinal

Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence have been reported in 1 to 5 of 1,000 patients.

Miscellaneous

Each of the following has been reported in 1 to 5 of 1,000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Reversible alopecia has been reported infrequently.

The following adverse reactions have been reported in patients taking nadolol and/or other beta-adrenergic blocking agents, but no causal relationship to nadolol has been established.

Central Nervous System

Reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability with slightly clouded sensorium, and decreased performance on neuropsychometrics.

Gastrointestinal

Mesenteric arterial thrombosis; ischemic colitis; elevated liver enzymes.

Hematologic

Agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura.

Allergic

Fever combined with aching and sore throat; laryngospasm; respiratory distress.

Miscellaneous

Pemphigoid rash; hypertensive reaction in patients with pheochromocytoma; sleep disturbances; Peyronie's disease. The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with nadolol.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Nadolol can be removed from the general circulation by hemodialysis. In addition to gastric lavage, the following measures should be employed, as appropriate. In determining the duration of corrective therapy, note must be taken of the long duration of the effect of nadolol.

Excessive Bradycardia

Administer atropine (0.25 to 1 mg). If there is no response to vagal blockade, administer isoproterenol cautiously.

Cardiac Failure

Administer a digitalis glycoside and diuretic. It has been reported that glucagon may also be useful in this situation.

Hypotension

Administer vasopressors, e.g., epinephrine or levarterenol. (There is evidence that epinephrine may be the drug of choice.)

Bronchospasm

Administer a beta₂-stimulating agent and/or a theophylline derivative.

DOSAGE AND ADMINISTRATION

DOSAGE MUST BE INDIVIDUALIZED. NADOLOL TABLETS MAY BE ADMINISTERED WITHOUT REGARD TO MEALS.

Angina Pectoris

The usual initial dose is 40 mg nadolol tablets once daily. Dosage may be gradually increased in 40 to 80 mg increments at 3 to 7 day intervals until optimum clinical response is obtained or there is pronounced slowing of the heart rate. The usual maintenance dose is 40 or 80 mg administered once daily. Doses up to 160 or 240 mg administered once daily may be needed. The usefulness and safety in angina pectoris of dosage exceeding 240 mg per day have not been established. If treatment is to be discontinued, reduce the dosage gradually over a period of one to two weeks (see **WARNINGS**).

Hypertension

The usual initial dose is 40 mg nadolol tablets once daily, whether it is used alone or in addition to diuretic therapy. Dosage may be gradually increased in 40 to 80 mg increments until optimum blood pressure reduction is achieved. The usual maintenance dose is 40 or 80 mg administered once daily. Doses up to 240 or 320 mg administered once daily may be needed.

Dosage Adjustment in Renal Failure

Absorbed nadolol is excreted principally by the kidneys and, although nonrenal

elimination does occur, dosage adjustments are necessary in patients with renal impairment. The following dose intervals are recommended:

Creatinine Clearance (mL/min/1.73m ²)	Dosage Interval (hours)
>50	24
31 to 50	24 to 36
10 to 30	24 to 48
<10	40 to 60

HOW SUPPLIED

Nadolol Tablets, USP **20 mg** are supplied as white to off-white, round tablets debossed with "AA" & "76" separated by a score mark on one side and plain on the other side.

They are available as follows:

Bottle of 30 Tablets:	NDC 69238-1123-3
Bottle of 90 Tablets:	NDC 69238-1123-9
Bottle of 1,000 Tablets:	NDC 69238-1123-1

Nadolol Tablets, USP **40 mg** are supplied as white to off-white, round tablets debossed with "AA" & "79" separated by a score mark on one side and plain on the other side.

They are available as follows:

Bottle of 30 Tablets:	NDC 69238-1124-3
Bottle of 90 Tablets:	NDC 69238-1124-9
Bottle of 1,000 Tablets:	NDC 69238-1124-1

Nadolol Tablets, USP **80 mg** are supplied as white to off-white, round tablets debossed with "AA" & "99" separated by a score mark on one side and plain on the other side.

They are available as follows:

Bottle of 30 Tablets:	NDC 69238-1125-3
Bottle of 90 Tablets:	NDC 69238-1125-9
Bottle of 1,000 Tablets:	NDC 69238-1125-1

STORAGE

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from light. Keep bottle tightly closed.

Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Oral Solid Dosage Unit Ahmedabad 382213, INDIA

Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 08-2017-01

PRINCIPAL DISPLAY PANEL NDC 69238-1123-3 Nadolol Tablets USP, 20 mg Rx only 30 Tablets Amneal Pharmaceuticals



NDC 69238-1124-3

Nadolol Tablets USP, 40 mg

Rx only

- 30 Tablets
- **Amneal Pharmaceuticals**



NDC 69238-1125-3

Nadolol Tablets USP, 80 mg

Rx only

30 Tablets

Amneal Pharmaceuticals



NADOLOL							
nadolol tablet							
Product Informa	ation						
Product Type		HUMAN PRESCRIPTION DRU	JG	Item	Code (Source)	ND	C:69238-1123
Route of Administr	ation	ORAL					
Active Ingredien	t/Active	Moiety					
	Ingred	ient Name			Basis of Stre	ngth	Strength
NADOLOL (UNII: FEN50)4330V) (NAE	OOLOL - UNII:FEN504330V)			NADOLOL		20 mg
Inactive Ingredie	ents						
		Ingredient Name					Strength
CELLULOSE, MICROC							
MAGNESIUM STEARA		097M6I30)					
POVIDONE (UNII: FZ98							
STARCH, CORN (UNII:	08232NY35])					
Product Charact	eristics						
Color	white (Of	f-white)	Score	3		2 p	oieces
Shape	ROUND		Size			7m	ım
Flavor			Impri	nt Co	de	AA	:76
Contains							
Packaging							
# Item Code	Pa	ckage Description		Ma	rketing Start Date	Mar	keting End Date

Marketing Marketing Category	Information Application Number or Monograph Citation	Marketing Start Date 06/02/2017	Marketing End Date
Marketing	Application Number or Monograph	-	-
Marketing	Information		
NDC:69238- 1123-1	1000 in 1 BOTTLE; Type 0: Not a Combination Product	06/02/2017	
NDC:69238- 1123-9	90 in 1 BOTTLE; Type 0: Not a Combination Product	06/02/2017	
1123-3	Product	06/02/2017	

	DOLOL olol tablet								
Pro	oduct Infor	mation							
Pro	duct Type		HUMAN PRESCRIPTION DRUG Item Code (Source)		NDC	:69238-1124			
Rou	ute of Admini	stration	ORAL						
Act	tive Ingredi	ent/Active	Moiety						
	-	Ingred	ient Name			Basis of Stre	ngth	Strength	
NAD	OLOL (UNII: FEI	N504330V) (NAI	OOLOL - UNII:FEN504330V)		١	NADOLOL	-	40 mg	
Ina	ctive Ingre	dients							
			Ingredient Name					Strength	
			E (UNII: OP1R32D61U)						
			097M6I30)						
	IDONE (UNII: F2 RCH, CORN (UI		1)						
JIA		uni 0023211133]/						
Pro	oduct Chara	acteristics							
Cole	or	white (Of	f-white)	Score	9		2 pi	eces	
Sha	ре	ROUND		Size			9mi	9mm	
Flav	vor			Impri	nt Coo	de	AA;	79	
Con	itains								
Pac	ckaging								
#	ltem Code	Pa	ckage Description		Mar	keting Start Date	Marl	keting End Date	
	DC:69238- 124-3	30 in 1 BOTTL Product	E; Type 0: Not a Combinati	on	06/02/	2017			

-	NDC:69238- 1124-1	1000 in 1 BOT Product	TLE; Type 0: Not a Combina	ation 0	06/02/2017			
Μ	arketing	Informat	ion					
Marketing CategoryApplication Number or Monograph CitationMarketing Start Date						Мат	keting End Date	
ANI	DA	ANDA20883	32		06/02/2017			
	ADOLOL dolol tablet							
Pı	roduct Infoi	mation						
Pr	oduct Type		HUMAN PRESCRIPTION DRU	JG	tem Code (Source)	NDC	:69238-1125	
Ro	oute of Admin	istration	ORAL					
Ac	tive Ingred	ient/Active	Moiety					
	Ingredient Name Basis of Strengt					nath	gth Strength	
		:N504330V) (NA	DOLOL - UNII:FEN504330V)		NADOLOL	y	80 mg	
In	active Ingre	N504330V) (NA	DOLOL - UNII:FEN504330V) Ingredient Name				-	
In CE	active Ingre	edients Rocrystallin	DOLOL - UNII:FEN504330V) Ingredient Name IE (UNII: OP1R32D61U)				80 mg	
In CE MA	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70	DOLOL - UNII:FEN504330V) Ingredient Name IE (UNII: OP1R32D61U)				80 mg	
In CE MA PO	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 Z 989GH94E)	DOLOL - UNII:FEN504330V) Ingredient Name IE (UNII: OP1R32D61U) 0097M6I30)				80 mg	
In CE MA PO	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 Z 989GH94E)	DOLOL - UNII:FEN504330V) Ingredient Name IE (UNII: OP1R32D61U) 0097M6I30)				80 mg	
In CE MA PO ST	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 Z 989GH94E) INII: 08232NY35	DOLOL - UNII:FEN504330V) Ingredient Name IE (UNII: OP1R32D61U) 0097M6I30)				80 mg	
In CE MA PO ST	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 Z 989GH94E) INII: 08232NY35	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) SJ)	Score			80 mg	
In CE MA PO ST PO	active Ingre LLULOSE, MICI AGNESIUM STEA VIDONE (UNII: F ARCH, CORN (U roduct Char	edients ROCRYSTALLIN RATE (UNII: 70 2989GH94E) INII: 08232NY39 acteristics	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) SJ)	Score			80 mg Strength eces	
In CE MA PO ST Co Sh	active Ingre LLULOSE, MICI AGNESIUM STEA VIDONE (UNII: F ARCH, CORN (U roduct Char	edients ROCRYSTALLIN ARATE (UNII: 70 Z 989GH94E) INII: 08232NY35 acteristics white (O	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) SJ)	Size		2 pi	80 mg Strength ecces	
In CE MA PO ST Co Sh Fla	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 Z 989GH94E) INII: 08232NY35 acteristics white (O	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) SJ)	Size	NADOLOL	2 pi 11n	80 mg Strength ecces	
In CE MA PO ST Co Sh Fla Co	active Ingre LLULOSE, MICH AGNESIUM STEA VIDONE (UNII: F ARCH, CORN (U roduct Char ape avor ontains	edients ROCRYSTALLIN ARATE (UNII: 70 Z 989GH94E) INII: 08232NY35 acteristics white (O	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) SJ)	Size	NADOLOL	2 pi 11n	80 mg Strength ecces	
In CE PO ST Co Sh Fla Co	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 72989GH94E) INII: 08232NY39 Acteristics white (0 ROUND	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) SJ)	Size	NADOLOL	2 pi 11n AA;	80 mg Strength ecces hm 29 keting End	
In CE MA PO ST Co Sh Fla Co Pa #	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 72989GH94E) INII: 08232NY39 acteristics white (0 ROUND	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) SJ) ff-white)	Size Imprin	NADOLOL	2 pi 11n AA;	80 mg Strength eces nm 99	
In CE PO ST Co Sh Fla Co Pa #	active Ingre	edients ROCRYSTALLIN ARATE (UNII: 70 72 989GH94E) INII: 08232NY35 Acteristics white (O ROUND Pa 30 in 1 BOTTL Product	DOLOL - UNII:FEN504330V) Ingredient Name E (UNII: OP1R32D61U) 0097M6I30) GJ) ff-white) ckage Description	Size Imprin	NADOLOL	2 pi 11n AA;	80 mg Strength ecces hm 29 keting End	

Marketing Information					
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date		
ANDA	ANDA208832	06/02/2017			

Labeler - Amneal Pharmaceuticals NY LLC (123797875)

Establishment					
Name	Address	ID/FEI	Business Operations		
Amneal Pharmaceuticals Private Limited		650762060	analysis(69238-1123, 69238-1124, 69238-1125) , label(69238-1123, 69238- 1124, 69238-1125) , manufacture(69238-1123, 69238-1124, 69238-1125) , pack(69238-1123, 69238-1124, 69238-1125)		

Revised: 12/2023

Amneal Pharmaceuticals NY LLC